Transmedics Group Inc
NASDAQ:TMDX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
61.07
150.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Transmedics Group Inc
NASDAQ:TMDX
|
4.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
187.8B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
186.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
137.1B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
135.7B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
129.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
48.1B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
55.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.6B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.8B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Transmedics Group Inc
Glance View
TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists. Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Transmedics Group Inc is 60.3%, which is below its 3-year median of 63.2%.
Over the last 3 years, Transmedics Group Inc’s Gross Margin has decreased from 71.9% to 60.3%. During this period, it reached a low of 59.3% on Sep 30, 2024 and a high of 71.9% on Sep 30, 2022.